Form 4: TELA Bio Director Boosts Stake with Equity Grants

TELA Bio, Inc. Director William J. Plovanic reported the acquisition of 11,925 restricted stock units and options to purchase 17,550 shares of common stock.

Summary

• William J. Plovanic, a Director of TELA Bio, Inc. (TELA), acquired 11,925 shares of common stock in the form of restricted stock units (RSUs) on October 31, 2025.
• These RSUs were acquired at a price of $0 per share and will vest in three equal annual installments beginning on October 31, 2026, contingent on continued service.
• Plovanic also acquired options to purchase 17,550 shares of common stock on October 31, 2025, with an exercise price of $1.23 per share.
• The options were acquired at a price of $0 and will vest in 36 equal monthly installments on each monthly anniversary of October 31, 2025, also subject to continued service.
• Following these transactions, Plovanic beneficially owns 11,925 shares of common stock directly and 17,550 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation for a director, which is generally viewed positively as it aligns the director's financial interests with those of the shareholders, fostering long-term commitment and performance.

Positives

• The acquisition of restricted stock units and stock options by a director indicates increased alignment of management's interests with those of shareholders.
• Equity grants are a standard method of incentivizing directors and retaining talent, linking their compensation to the company's long-term performance.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon William J. Plovanic's continued service through the applicable vesting dates, meaning the full benefit is not guaranteed if service ceases.

Future Outlook

The filing details future vesting schedules for equity grants, with restricted stock units vesting annually starting October 31, 2026, and stock options vesting monthly over 36 months from October 31, 2025, both subject to continued service.

Industry Context

Equity grants to directors, such as restricted stock units and stock options, are a common practice across industries, particularly in the biotech and medical device sectors, to align the interests of board members with long-term shareholder value creation. This transaction is a routine compensation event.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and stock options as part of director compensation is a standard practice in the biotechnology and medical device industry, comparable to compensation structures seen at companies like Integra LifeSciences Holdings Corporation or CONMED Corporation.
• The vesting schedules (three-year annual for RSUs, three-year monthly for options) are typical for long-term incentive plans designed to retain talent and encourage sustained performance, aligning with benchmarks for director equity compensation.

Related Party Transactions

• The acquisition of restricted stock units and stock options by William J. Plovanic, a director, represents a compensation transaction between the company and a related party. This is a standard form of director compensation.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with shareholder interests, potentially leading to more focused long-term value creation.
• Employees: While not directly impacting all employees, the compensation structure for directors can reflect broader company policies on equity incentives.

Next Steps

• The restricted stock units will begin vesting in three equal annual installments starting October 31, 2026.
• The stock options will vest in 36 equal monthly installments on each monthly anniversary of October 31, 2025.

Key Dates

Keywords

TELA Bio, TELA, Form 4, insider transaction, restricted stock units, stock options, director compensation, equity grant, William J. Plovanic